Summary
This program aims to determine the host cell mechanisms underlying SARS-CoV-2-mediated tissue damage, inflammation, and coagulopathy in various organs, and to identify novel therapeutic targets for COVID-19 and Long-COVID.
Role of the Non-canonical Inflammasome in SARS-CoV-2-mediated Pathology and Coagulopathy
US · IL
NIH
grant
awarded
#nih-5P01AI175399-03
What they want
The program will investigate host cell mechanisms causing tissue damage and altered immune responses in the lung (Project 1), and in the brain and blood circulation (Project 2) due to SARS-CoV-2 infection. It will also identify and target host mechanisms controlling multi-organ inflammatory pathologies, synergizing with efforts to target cellular enzymes for viral replication (Project 3). The ultimate goal is to reveal and test novel therapeutic targets to manage inflammation, neuroinflammation, thrombosis, and restrict viral replication. Support will be provided by four Cores offering administration, biostatistical/bioinformatic support, animal models, purified viral strains, and primary cell types with genetic manipulations.
Deliverables
- Identification of host cell mechanisms underlying tissue damage in the lung, brain, and blood circulation
- Understanding how SARS-CoV-2 alters immune responses
- Identification and testing of novel therapeutic targets to tame inflammation, neuroinflammation, thrombosis, and restrict viral replication
